The diagnosis came on a Tuesday, which felt like something—a day associated with mystery and bad luck, as if the universe had a sense of humor. Early-stage pulmonary adenocarcinoma. Stage I. James "Jimmy" O'Sullivan was thirty years old, and the doctor said he had eighteen to twenty-four months if he did nothing. Six to eight if he waited.

"The Keystone Treatment extends lifespan to two hundred and fifty years," the doctor said, sliding a brochure across the desk. "But the contribution agreement requires thirty years of service to Apex Biosciences after the procedure. It's non-negotiable."

Jimmy picked up the brochure. Keystone Treatment: Extending Tomorrow, printed in clean sans-serif font on heavy cream paper. It looked like an invitation to a wedding, not a contract for biological slavery.

"What kind of service?" he asked.

"Whatever Apex determines. Research. Data analysis. Field deployment. They'll match your skills."

"My skills are analyzing financial statements for a mid-tier logistics company."

"Their algorithms will match you to an appropriate role."

Three days later, Jimmy sat in a shipping-container apartment off Third Street, looking at the Bay Bridge through a window the size of a door, and listened to Sarah breathe in the bedroom behind him.

She had gotten the Keystone Treatment three months ago—not for illness, but because Apex had offered it "free of charge" in exchange for exclusive rights to all her journalistic work. She was an investigative reporter for the Bay Free Press. Her story on venture capital tax evasion had been making waves. Then she got the Treatment, and the waves stopped.

Not literally. Sarah still spoke, still ate, still functioned. But she stopped laughing. Stopped calling her mother. Stopped asking how his day was.

The morning he told her about the cancer, she had looked at him for exactly six seconds, processed the information, and said: "Have you decided on the Treatment?"

"Steroid," Jimmy said. That was what their grandmother used to call it—a word from the old country that meant "artificial" or "false." The Treatment made you live longer but changed something fundamental. Something you couldn't name until it was gone.

He found Marcus Reid on a Thursday, through a contact at the free clinic where he'd gone for a second opinion. Marcus's office was above a laundromat in Hunter's Point, the kind of place where the fluorescent light flickered in a rhythm that suggested Morse code.

Marcus was a tall Black man with the lean build of someone who ran more than he sat, and eyes that had seen too many versions of the same story told by different companies.

"Keystone," he said, not as a question. "You heard about the empathy decay."

"I heard there were side effects."

"Side effects." Marcus laughed, a short dry sound. "That's what Apex calls it. 'Emotional modulation.' They rebranded it. You get the Treatment, your emotional variance drops by approximately forty percent over the first two years. Less grief, less anxiety, less passion. You become a very efficient machine for processing data and generating profit."

"Why didn't anyone report this?"

"Because Sarah O'Connor can't report it anymore. Apex owns her contract. And because the FDA approved Keystone under emergency medical provisions—the lung cancer indication is legitimate. Nobody dies from waiting for Keystone. People die from not getting it. So the trade-off is framed as 'life versus side effects' instead of 'life versus life.'"

Jimmy stared at the water stain on the ceiling that looked vaguely like Ireland. "What do I do?"

Marcus pulled a folder from his desk. Inside were slides showing brain scans—before and after Keystone Treatment. The difference was subtle but undeniable. The prefrontal cortex showed reduced activity in the areas associated with empathetic response and creative thinking.

"I have forty percent survival with my alternative protocol," Marcus said. "Gene therapy using a CRISPR variant we developed. It's not approved. It's not clean. But it treats the cancer without turning you into a machine."

"Forty percent."

"You can also take Keystone, live to two hundred and fifty, and stop caring that you're alive." Marcus leaned forward. "The choice is yours, Jimmy. But whatever you choose, choose it before Sarah chooses for you."

He chose on a Saturday, after watching Sarah sit at the kitchen table for two hours writing an article she would never publish. She was typing with mechanical precision, every keystroke exact, every sentence grammatically flawless and emotionally empty.

He went to Marcus's office at 9 PM. Told him he wanted the alternative protocol.

Marcus nodded and began preparing the injection.

The leak happened four days later.

Jimmy never found out who did it—maybe Marcus, maybe someone inside Apex. But at 6 AM on Monday, a package arrived at every major news outlet in the country, containing Apex's internal research on Keystone empathy decay. Full data. Forty-two brain scans. Twelve pages of internal memos where executives discussed "optimizing the emotional profile" of long-term patients.

By noon, Apex's stock had dropped thirty-four percent. By evening, Congress announced hearings.

Jimmy sat in Marcus's clinic, feeling the first burn of the gene therapy as it entered his bloodstream. It felt like fire diluted with ice.

"They're going to shut Keystone down," he said.

"Not shut it down. Regulate it. There's a difference. People are going to keep taking it—they're afraid of dying, Jimmy. Fear is a powerful motivator."

"I found out something else," Jimmy said. "Before I came today. Apex isn't just modifying emotion. They're collecting cellular samples from every patient. Brain tissue. I talked to a lab technician—Dr. Victoria Chen, she works in oncology at UCSF. She told me that every Keystone patient provides a quarterly blood sample. But they're also extracting neural tissue. Small amounts. Enough for full cortical mapping."

Marcus stopped preparing the injection. "Why?"

"To build models," Jimmy said. "If they can map how Keystone changes a brain, they can predict how it will change you before you take it. They can sell those models. Or use them to create—what? Better workers? Soldiers?"

Marcus set down the syringe. "You know what the irony is? Your cancer is Stage I. The alternative protocol has a sixty percent chance of curing you completely. But you're spending your last conscious moments of a normal lifespan trying to stop other people from making the same choice you made."

"Someone has to."

"Jimmy—"

"I took the choice," he said. "Now let them take theirs."

The injection went in. It hurt worse than he expected. But as the fire spread through his veins, he thought of Sarah—at the table, typing her unwritten article, her face smooth and calm and empty. And he knew, with a certainty that was both terrible and clear, that he would rather die as a man who cared than live as a machine that didn't.

Six weeks later, his lungs were clear. The scans showed zero evidence of disease. He stood on the pier at Pier 39, watching the fog roll in over Alcatraz, and felt something he hadn't felt in months.

Fear. Not of death. Of life. Of everything he might lose, everything he might gain, everything that was uncertain and fragile and beautiful precisely because it could end.

Behind him, in the clinic, Sarah visited his apartment. Found his journal. Read his last entry:

"Today I chose to die as myself. If that's arrogance, so be it. At least when I go, I'll go knowing I was alive."

She read it three times. Then she sat on the floor of the empty apartment and, for the first time in a year, cried.

--- © OBJECTIVE TENSOREAN MATHEMATICAL ENCODING SYSTEM v2.0 (OTMES-v2) Code: OTMES-v2-28192832-B9-M7-012-1770-64B162 E_total: 18.50 Dominant Mode: M7 (Sci-Fi, intensity 8.5) Dominant Angle: 55.0° (Sublime Type - Exploration-Advancement) Tensor Rank: 8 Irreversibility Index: 0.60 M-Vector (10D): [4.0, 2.5, 4.0, 5.0, 6.0, 6.5, 3.5, 8.5, 4.0, 6.0] N-Vector (Active/Passive): [0.75, 0.25] K-Vector (Sensible/Rational): [0.40, 0.60] TI (Tragedy Index): 62.0 (T2 Disillusionment Level, Optimistic Bias)